CA2100657A1 - Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes - Google Patents

Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes

Info

Publication number
CA2100657A1
CA2100657A1 CA002100657A CA2100657A CA2100657A1 CA 2100657 A1 CA2100657 A1 CA 2100657A1 CA 002100657 A CA002100657 A CA 002100657A CA 2100657 A CA2100657 A CA 2100657A CA 2100657 A1 CA2100657 A1 CA 2100657A1
Authority
CA
Canada
Prior art keywords
sodium chondroitin
chondroitin sulfate
effective amount
shark
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002100657A
Other languages
English (en)
Inventor
Glen M. Hartung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARTHRO RESEARCH AND DEVELOPMENT Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2100657A1 publication Critical patent/CA2100657A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002100657A 1991-11-15 1992-11-16 Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes Abandoned CA2100657A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79260791A 1991-11-15 1991-11-15
US07/792,607 1991-11-15

Publications (1)

Publication Number Publication Date
CA2100657A1 true CA2100657A1 (fr) 1993-05-16

Family

ID=25157479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002100657A Abandoned CA2100657A1 (fr) 1991-11-15 1992-11-16 Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes

Country Status (3)

Country Link
EP (1) EP0571597A4 (fr)
CA (1) CA2100657A1 (fr)
WO (1) WO1993009766A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380366B1 (en) 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
RU2195946C2 (ru) 1997-03-11 2003-01-10 Ле Лабораториз Аетерна Инк. Противоопухолевые терапевтические средства, включающие комбинацию экстракта хряща и антинеопластического агента, обеспечивающие высокую эффективность действия при низких токсических побочных эффектах
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
AU2745700A (en) 1999-02-01 2000-08-18 Dermal Research Laboratories, Inc. A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
ES2167251B1 (es) 2000-07-13 2003-09-16 Bioiberica Nuevos disacaridos con accion antiartrosica.
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
JP4754066B2 (ja) 2000-12-22 2011-08-24 株式会社林原生物化学研究所 抗関節障害剤
EP1308155B1 (fr) * 2001-10-12 2006-06-21 Nipro Corporation Solution injectable contenant un colloide de fer et chondroitine sulfate de cartilage de requin
JP2003335698A (ja) 2002-05-20 2003-11-25 Maruha Corp 高尿酸血症治療又は予防用組成物
US20040132689A1 (en) * 2002-12-27 2004-07-08 Seiji Nishida Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid
FR2867981B1 (fr) * 2004-03-24 2008-10-31 Genevrier Sa Lab Utilisation des chondroitine mono-et disulfates en therapeutique
ES2327480B1 (es) 2007-06-15 2010-08-10 Bioiberica, S.A. "disacaridos para el tratamiento de tendones, ligamentos y huesos".

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US7772210B2 (en) 2003-02-19 2010-08-10 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8084441B2 (en) 2003-02-19 2011-12-27 Stellar Pharmaceuticals, Inc. Cystitis treatment with high dose chondroitin sulfate
US8334276B2 (en) 2003-02-19 2012-12-18 Stellar Pharmaceuticals Inc. Cystitis treatment with high dose chondroitin sulfate
US8778908B2 (en) 2003-02-19 2014-07-15 Stellar International Inc. Cystitis treatment with high dose chondroitin sulfate

Also Published As

Publication number Publication date
WO1993009766A1 (fr) 1993-05-27
EP0571597A4 (en) 1994-06-01
EP0571597A1 (fr) 1993-12-01

Similar Documents

Publication Publication Date Title
CA2100657A1 (fr) Methode de traitement des arthropathies algiques aigues et chroniques chez l'homme et chez d'autres mammiferes
AU655935B2 (en) Pharmaceutical composition of florfenicol
DE69024039T2 (de) Behandlung von pathologischen zuständen und krankheiten.
US6645948B2 (en) Nutritional composition for the treatment of connective tissue
RU2001116077A (ru) Способ лечения церебральных ишемий, а также применение эритропоэтина или производных эритропоэтина для лечения церебральных ишемий
US4604391A (en) Treatment of osteitis and osteomyelitis employing thiadiazine compounds
DE69013797T2 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
JPH08501317A (ja) 抗菌性インターフェロン誘発性医薬品
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
KR102285724B1 (ko) Dna 단편 혼합물 및 히알루론산을 포함하는 연골 재생용 조성물
WO1991002529A2 (fr) Produit et methode pour tuer les cellules anormales chez les vertebres
US5278172A (en) Method and composition for treating tendon or joint inflammation using a vasodilator
DE19961141A1 (de) Pharmazeutische Zusammensetzung aus Spinnengiften sowie deren Herstellung und Verwendung zur Behandlung von Tumorerkrankungen
DE69531166T2 (de) Arzneistoff zur erleichterung der durch immunsuppressiva verursachten nebenwirkungen
RU1836084C (ru) Способ получени препарата дл лечени паразитарных заболеваний животных
DE102011003478A1 (de) Antivirales Mittel enthaltend rekombinante Mistellektine
KR20220152904A (ko) Dna 분획물 및 콘드로이틴 설페이트를 포함하는 관절염 예방 또는 치료용 조성물
RU2349339C1 (ru) Средство, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, стимулирующим регенерацию хрящевой и соединительной ткани свойствами
DE69230644T2 (de) Verwendung von protease nexin-i als mittel gegen entzündungen
DE3612232A1 (de) Verwendung von menschlichem urogastron zur foerderung der heilung von knochen und/oder sehnen
US6218433B1 (en) Use of pharmaceutical composition in the treatment of traumatic arthritis in horses
US12059430B2 (en) Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
JPS62252729A (ja) 造血機能回復促進剤
RU2088239C1 (ru) Состав, проникающий через кожу, для лечения остеоартроза
CA2446615C (fr) Composition nutritionnelle pour le traitement du tissu conjonctif

Legal Events

Date Code Title Description
FZDE Discontinued